High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms
  • Hematopoietic Stem Cell Transplantation

abstract

  • Adjuvant HDC with AHST prolonged RFS in high-risk primary breast cancer compared with control, but this did not translate into a significant OS benefit. Whether HDC benefits patients in the context of targeted therapies is unknown.

publication date

  • August 20, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4322115

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.5910

PubMed ID

  • 21768471

Additional Document Info

start page

  • 3214

end page

  • 23

volume

  • 29

number

  • 24